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AOGS LETTER TO THE EDITOR
Evidence on the use of tranexamic acid at cesarean delivery
Sir,
We thank Dr. Sentilhes and colleagues for their interest in our
publication (1). We agree that the statistical and clinical hetero-
geneity within the studies is high. However, a random effect
model was used to pool data. Under this model we allow that the
true effect could vary from study to study. Therefore, even if
there is significant heterogeneity between the studies, the weights
assigned under random effects are balanced. Regarding the qual-
ity of the studies, most of the included trials are judged to be low
risk of selection bias and were double-blind.
Regarding the safety of tranexamic acid (TXA), no significant
increase in the incidence of thrombotic events related to TXA
has been observed in any studies of TXA among pregnant
women, including randomized controlled trials (RCTs).
Although most of the RCTs included small samples with inade-
quate power to assess the risk of adverse effects, the meta-analy-
sis pooled data from more than 2000 women. The WOMAN
trial (http://www. thewomantrial.lshtm.ac.uk) intends to deter-
mine the effect of the early administration of TXA in women
with a clinical diagnosis of postpartum hemorrhage. It will have
the power to assess severe objective maternal morbidity as well
as such severe adverse events as thromboembolic events.
The correlation between TXA administration and acute renal
failure due to thrombosis-induced cortical necrosis refers to five
published case reports, four of these including patients with risk
factors for ischemic renal damage and acute renal cortical necro-
sis. Moreover, acute renal failure and renal cortical necrosis have
been described following severe PPH without any TXA treat-
ment (2). We agree that it would be beneficial to accumulate
more data regarding the safety of TXA in pregnancy, but clearly
the pregnancy and non-pregnancy data so far are very reassur-
ing, including data on thousands of pregnant women.
The successful use of TXA in various non-obstetric periopera-
tive settings confirms that TXA is both efficacious and safe. Evi-
dence from 211 RCTs (20 781 participants) showed that TXA
reduced the risk of blood transfusion and the mean transfused
volume, regardless of the type of surgery, including cardiac,
orthopedic, hepatic, urological, and vascular (3). Moreover,
there was no evidence of an increased risk of thrombotic events.
These data should be reassuring to Dr. Sentilhes et al.
There is a clear theoretical rationale for the use of antifibri-
nolytic agents to reduce postpartum blood loss. In fact, both the
coagulation and fibrinolysis processes are implicated in the con-
trol of postpartum blood loss, supporting the hypothesis that
TXA may be effective in PPH prevention (4). Moreover, the effi-
cacy of TXA in menorrhagia suggests that it can reduce uterine
blood loss, even of low volume and in a nonsurgical context (5).
Overall, while we understand Sentilhes et al.’s concern, we
would like the reader to concentrate on the large amount of
data already published showing the safety and efficacy of TXA
for prevention of postpartum hemorrhage at cesarean delivery.
The time has arrived for better prevention of one of the biggest
killers of pregnant women around the world.
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